

Article

Not peer-reviewed version

Antibacterial Properties of Peptide and Protein Fractions from the Cornu aspersum Mucus

[Lyudmila Velkova](#) , [Aleksandar Dolashki](#) , Ventsislava Petrova , [Emiliya Pisareva](#) , Dimitar Kaynarov , Momchil Kermedchiev , Marya Todorova , [Pavlina Dolashka](#) *

Posted Date: 29 April 2024

doi: 10.20944/preprints202404.1943.v1

Keywords: Cornu aspersum mucus; antimicrobial peptides; de novo MS/MS sequencing; proteomic analysis; mucus proteins whit antimicrobial action



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Antibacterial Properties of Peptide and Protein Fractions from the *Cornu aspersum* Mucus

Lyudmila Velkova ^{1,*}, Aleksandar Dolashki ¹, Ventsislava Petrova ², Emiliya Pisareva ²,
Dimitar Kaynarov ¹, Momchil Kermedchiev ¹, Marya Todorova ¹ and Pavlina Dolashka ^{1,*}

¹ Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 9, 1113 Sofia, Bulgaria; adolashki@yahoo.com or aleksandar.dolashki@orgchm.bas.bg (A.D.); mitkokaynarov@abv.bg (D.K.); kermedchiev@yahoo.com (M.K.); krasimirova_m@yahoo.com (M.T.)

² Faculty of Biology, Sofia University, 8 Dragan Tzankov blvd., 1164 Sofia, Bulgaria; v.petrova@biofac.uni-sofia.bg (V.P.) episareva@uni-sofia.bg (E.P.)

* Correspondence: lyudmila.velkova@orgchm.bas.bg or lyudmila_velkova@abv.bg (L.V.); pda@abv.bg (P.D.)

Abstract: The study of biologically active substances from natural sources shows the prospect of obtaining a new type of antimicrobial agents, highly effective against pathogenic microorganisms and non-toxic to humans. Our study reveals for the first time that *Cornu aspersum* mucus has the potential to act as a source of antibacterial agents against bacterial pathogens such as *Bacillus cereus* 1085, *Propionibacterium acnes* 1897, *Salmonella enterica* 8691, *Enterococcus faecalis* 3915, and *Enterococcus faecium* 8754. Both mucus fractions with MW<20 kDa and MW>20 kDa showed antimicrobial activity and antioxidant properties that's why they can be turned into an alternative agent to expensive synthetic antibacterial compounds. Using *de novo* sequencing 16 novel peptides with potential antibacterial activity were identified by in a fraction with MW<20 kDa. The results of electrophoretic and proteomic analysis of mucus fraction with MW >20 kDa presented proteins with potential antibacterial activity highly homologous to hemocyanins, mucus protein Aspermin, lectins, L-amino acid oxidase-like protein, and mucins (mucin-5AC, mucin-5B, mucin-2 and mucin-17). Thanks to the synergistic action of the bioactive components, the mucus fraction with MW > 20 kDa in low concentrations per 8–2 µg/mL showed promising antimicrobial activity against the tested bacteria, comparable to Vancomycin and without unwanted cytotoxic effects against non-target cells. Additionally, *C. aspersum* mucus fractions were found to have a positive effect on eukaryotic organisms by reducing the levels of intracellular oxidative damage and increasing the antioxidant capacity of the cell. These findings could serve as a basis for the development of a potent non-cytotoxic antibacterial agent to replace conventional antibiotics and avoid the development of antibiotic resistance.

Keywords: *Cornu aspersum* mucus; antimicrobial peptides; *de novo* MS/MS sequencing; proteomic analysis; mucus proteins whit antimicrobial action

1. Introduction

The World Health Organization (WHO) has reported an alarming increase in the number of resistant bacterial strains to conventional antibiotics, which is a threat to public health safety [1]. Also, antibiotic resistance (AR) is a global problem with an important economic impact [2,3]. The causes of AMR are multifactorial, with the indiscriminate and prolonged use of antibiotics in both human and veterinary medicine and agriculture being paramount to the development and spread of drug-resistant microorganisms [4,5].

Bacteria are complex organisms and the effect of antibiotics on bacterial DNA is weak, but may provoke a new acquired resistance mechanism [6]. AMR is a public health problem, spreading through humans, animals (domestic and wild) and the environment (water and air) [4]. Antibiotic resistance is therefore a silent pandemic that requires global health solutions [7]. The problem of

antibiotic resistance necessitates an urgent search for alternatives to conventional antibiotics with new modes of action and less susceptibility to bacterial resistance.

Antimicrobial peptides (AMPs) derived from natural sources have been shown to exhibit broad-spectrum antimicrobial activity with high specificity and low toxicity and are an excellent option to combat antibiotic resistance [8]. The mode of action of AMPs relates to osmotic lysis due to interaction with the bacterial membrane. Research also demonstrates that AMPs result in membrane damage, inhibit macromolecular synthesis, damage cellular organelle and DNA, inhibit enzymes and regulate host immunity [9]. The presence of a cation-rich moiety and hydrophobic amino acids is typical in AMPs, resulting in a cationic arrangement with amphiphilic (hydrophilic and hydrophobic) characteristics [10,11]. This enables specificity to prokaryotic membranes, as mammalian cells have a net-neutral charge due to the presence of zwitterionic phospholipids, for example, phosphatidylethanolamine, phosphatidylcholine or sphingomyelin [11,12].

AMPs play a crucial role against various infections in invertebrate species, which, unlike vertebrates, do not have an adaptive immune system and, therefore, rely solely on innate defence mechanisms [13]. Invertebrate organisms of the phylum Mollusca represent one of the largest reservoirs of pharmacologically active compounds due to their great diversity (surpassed only by arthropods) and their ability to adapt to almost all types of habitats [14,15]. Bioactive compounds from haemolymph and mucus from gastropods have been shown to be powerful bioactive combinations with potential applications in combating pathogenic bacteria [16–24].

In the last decade, several studies reported antibacterial and antioxidant properties, as well as healing potential in treating wounds on the mucus of some land snails [16,19–21,24–27]. The antimicrobial activity of land snail mucus is known to be related not only to the presence of AMPs but also to some antibacterial proteins and glycoproteins [29]. A number of studies have reported that some proteins and glycoproteins in the mucus of various land snails (*Achatina fulica*, *H. aspersa*, *Cryptozona bistrialis*, *Lissachatina fulica* and *Hemiplecta differenta*) are responsible for the antimicrobial properties of extracts from these snails [20,21,24,28–32].

The presented analyses in the current study are on new natural compounds with antimicrobial activity that upgrade our previous studies on the antibacterial activity of *Cornu aspersum* snail mucus. New information is provided on the antibacterial activity of two mucus fractions with MW<20 and MW>20 kDa from *C. aspersum* against 5 pathogenic bacteria (*Bacillus cereus* 1085, *Propionibacterium acnes* 1897, *Salmonella enterica* 8691, *Enterococcus faecalis* 3915, and *Enterococcus faecium* 8754) and the identified important mucus components associated with antimicrobial activity.

2. Results

2.1. Preparation of Snail Mucus Extract

The mucus was collected from snails *C. aspersum*, growing in Bulgarian eco-farms using patented technology, without disturbing the biological functions of snails [17,19]. The resulting crude mucus extract was homogenized and centrifuged to remove coarse impurities. The purified native mucus extract was separated into 2 major fractions by ultrafiltration under pressure with polyethersulfone membrane filters with pore sizes of 20 kDa (Microdyn Nadir™ from STERLITECH Corporation, Goleta, CA, USA).

2.2. Analysis and Characteristics of the Isolated Mucus Fraction with MW < 20 kDa

After purification by RP-HPLC on a Nucleosil C18 column, the molecular masses of the bioactive compounds in the fraction with MW < 20 kDa (Figure 1) were identified by mass spectrometry.




Figure 1. Purification of RP-HPLC of mucus fraction with MW<20 kDa on a Nucleosil C18 column (250 mm x 10 mm) by gradient of water–acetonitrile (with 0.1% TFA) for 70 min at a flow rate of 1.0 mL/min.

2.2.1. Molecular Mass Analysis and de Novo Sequencing of Peptides by Mass Spectrometry

A thorough characterization of a fraction with MW < 20 kDa is presented by Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analyses (MALDI-TOF-MS analysis) in the range to 3 kDa (Figure 2) and a range between 3–20 kDa (Figure 3). The MS-spectrum presented in Figure 2 shows that the mucus fraction with MW < 3 kDa contained various peptides with different masses in the region between 900–3011 Da. Peptides determined as protonated molecule ions $[M + H]^+$ at m/z 1376 Da, 1438 Da, 1738 Da, 1796 Da, 1909 Da, 1966 Da, and 2292 Da dominate the MS-spectrum (Figure 2).




Figure 2. MALDI-ToF-MS spectrum of a fraction with MW < 3 kDa. Standard peptide solution was used to calibrate the mass scale of the Autoflex™ III High-Performance MALDI-TOF and TOF/TOF Systems (Bruker Daltonics, Bremen, Germany).




Figure 3. MALDI-ToF-MS spectrum of fraction with MW<20 kDa recorded in range 3–20 kDa. Standard peptide solution was used to calibrate the mass scale of the Autoflex™ III High-Performance MALDI-TOF and TOF/TOF Systems (Bruker Daltonics, Bremen, Germany).

Peptides and polypeptides with higher molecular weights detected in fraction with MW < 20 kDa are presented on MS-spectrum in Figure 3, as molecular protonated ions [M + H]⁺ at m/z 5573.742 Da, 6429.681 Da, 7337.199 Da, 11143.605 Da, 12464.216 Da, 15059.328 Da and 18005.169 Da as well as various other ions with lower intensity. The determined ions [M+H]⁺ at m/z 12.464 Da, 15059.328 Da and 18005.169 Da are in good agreement with similar proteins in snail mucus of *C. aspersum* [24,33], *Helix pomatia* [34] and *A. fulica* [35] reported previously.

The amino acid sequences (AAS) of low molecular peptides (with MW < 3 kDa) were identified by *de novo* sequencing experiments (MS/MS analysis) of the [M+H]⁺ ions. Following b- and y-fragmentation ions in MS/MS spectrum of peptide [M+H]⁺ at m/z 1966.11, the amino acid sequence LLLDNKGGGLVGGLGGGGKGGG was identified (Figure 4).




Figure 4. MALDI-MS/MS spectrum of peptide [M+H]⁺ at m/z 1966.11Da and its amino acidic sequence LLLDNKGGGLVGGLGGGGKGGG determined by *de novo* sequencing.

Thus, the amino acid sequences of 16 new peptides with molecular masses below 3000 Da were identified and AAS of another 6 peptides were confirmed (Table 1). The determined physicochemical characteristics of the identified peptides, such as isoelectric points (pI), grand average of hydropathicity (GRAVY), and net charge by the ExPASy MW/pI tool program and ExPASy ProtParam tool are presented in Table 1. The analysis showed the presence of both cationic and anionic, as well as neutral amphipathic peptide structures.

Table 1. The primary structures of the peptides with MW below 3 kDa, from a garden snail *C. aspersum*, identified by *de novo* sequencing in MALDI-MS/MS.

No	Amino Acid Sequence of Peptides	[M+H] ⁺ Da	Calcul. monois. mass Da	pI	GRAVY	Net Charge	Predicted by iAMPpred software		
							Antibacterial (%)	Antiviral (%)	Antifungal (%)
1	LLPFKEPDL	1071.60	1070.60	4.37	−0.600	−2/+1	28	51	19
2	ACGATLQLENCG	1179.77	1178.51	4.00	+0.350	−1/0	29.3	35.7	43.7
3	LNLGNGANGLVGG	1212.76	1211.63	5.52	+0.321	0/0	74.0	43.1	74.3
4	AGVGGAAGNPSTYVG	1277.70	1276.60	5.57	+0.260	0/0	25.1	7.4	11.3
5	GGGMVKEDGSCLGV	1308.77	1307.58	4.37	+0.207	−2/+1	40.4	31.4	33.7
6 ^a	MLGGGVNSLRPPK	1325.80	1324.73	11.0	−0.262	0/+2	22.8	14.0	8.9
7	CVGGAGGHGDSKAKGT	1376.53	1375.56	6.73	−0.106	−1/+1	85.2	48.8	74.4
8	GGGGYHTWGEKKF	1409.48	1408.62	6.75	−0.964	−1/+1	69.0	62.8	72.6
9	MLNVAVNKGEVKH	1438.86	1437.78	8.37	−0.138	−1/+2	56.4	38.0	19.7
10 ^b	NLVGGSGGGGRGGANPLG	1496.79	1495.75	9.75	−0.217	0/+1	66.0	33.7	48.2
11	GTMSPAGGEMGPVTAGVG	1576.04	1574.71	4.00	+0.250	−1/0	13.1	24.8	8.3
12	GTKGCGPGSCPPGDTVAGVG	1716.79	1715.76	5.82	−0.100	−1/+1	23.8	20.2	25.8
13 ^c	ACSLLLGGGGVGGGKGGGGHAG	1738.96	1737.86	8.27	+0.409	0/+1	82.6	49.5	67.0
14 ^a	LLLDGFGGGLLVEHDPGS	1796.00	1794.92	4.02	+0.439	−3/0	37	45	10
15 ^d	MGGWGGGLGGGHNGGWMPK	1852.96	1851.83	8.52	−0.611	0/+1	69	56.0	57.0
16 ^c	ACLTVDHFFAGMPCGGGP	1876.88	1875.81	5.08	+0.542	−1/0	32.4	42.6	20.1
17 ^c	NGLFGGLGGGGHGGGKGPGE	1909.98	1908.88	6.75	−0.487	−1/+1	89.5	67.2	79.5
18	LLLDNKGGGLVGGLLGGGKGGG	1966.11	1965.10	8.59	+0.322	−1/+2	93	56	81
19	GMVLLHCSPALDFHKTPAV	2036.09	2035.04	6.91	+0.616	−1/+1	18	53	14
20	LPFLGVGGLLGGSVGGGGGGGAPL	2136.24	2135.17	5.52	+1.023	0/0	66	33	36
21	MVLGKGGGGLLGGVLGGGKDAHLGG	2292.32	2291.21	6.50	+0.319	−2/+2	84.3	59.0	71
22	LLKDNGVGGGLGGGGAGGGGLVGGNLGG GAG	2478.39	2477.30	5.84	+0.439	−1/+1	86.4	54	66
23	KTSKLMVYLAGGGGGLGGVGGGGGGAG GGGPGGL	2843.76	2842.48	9.70	+0.374	0/+2	76	47	67

The AASs of these peptides were identified previously by ^a Dolashki et al., 2018 [36]; ^b Dolashki et al., 2020 [19]; ^c Topalova et al., 2022 [37]; ^d Velkova et al., 2018 [38].

The analysis showed the presence of cationic, anionic and neutral amphipathic peptide structures with generally hydrophobic surfaces, but 9 hydrophilic peptides were also identified (Nos. 1, 6–10, 12, and 15, Table 1). Based on the founded primary structures of peptides (Table 1) their antimicrobial activity was predicted using iAMPpred software (<http://cabgrid.res.in:8080/amppred>) (accessed on 6 March 2024), an extensive database [39]. The results showed that peptides Nos 3, 7, 8, 13, 17, 18, 20, 21–23, had the highest prognostic, antibacterial and antifungal activities, while peptides 8 and 17 had the highest prognostic antiviral activities.

The alignment of the AASs of peptides shown in Table 1 with database AMPs by CAMPSing software (<http://www.campsign.bicnirrh.res.in/blast.php>, accessed on 24 March 2024) revealed similarity with known antimicrobial peptides (presented in Supplementary Materials SI1). Peptides Nos 10, 13, 17, 18, 20, 21, 22, and 23 show high homology, with glycine-rich antimicrobial peptides—Procambarin, Holotricin, Microcin B, Acanthoscurrin and Ctenidin, with Gly/Leu rich antimicrobial peptide Leptoglycin, Glycine-rich protein GWK, while peptides Nos 7, 8, 12, and 15 revealed homologies with Defensin-like protein 196, Glycine-rich protein GWK, Crustin-like antimicrobial peptide, different forms of Gallinacin and Shepherin (presented in Supplementary Materials, SI1).

Presented evidence confirmed that identified mucus peptides belong to the AMP family. Furthermore, the obtained results can be considered as basic information in the study of bioactive peptides from the *C. aspersum* mucus extract and for their potential biomedical application.

2.2.2. Characterisation of Mucus Fraction with MW > 20 kDa by Electrophoretic and MALDI-MS Analyses

The electrophoretic profile determined by 12%-SDS-PAGE of mucus fraction from *C. aspersum* with MW > 20 kDa (at a concentration 1.4 mg/mL) clearly shows various protein bands with MWs major in the region between 20–200 kDa. The highest expression was observed for proteins with MW at 17.6 kDa, 26.71 kDa, 29–32 kDa, 39.115, between 48–60 kDa, 97.0 kDa and over 100 kDa (Figure 5A). Proteins with MW at 20.5 kDa, 23.6 kDa, 29.1 kDa, 35.93 kDa, 70.89 kDa, and 84.77 kDa are also present in the composition of the fraction with MW >20 kDa, although with a lower expression.




Figure 5. Analysis of molecular masses and protein intensities of 12% SDS-PAGE, scanned with a high resolution, using the ImageQuant™ TL v8.2.0 software. A) Electrophoretic pathway: 1) standard protein marker with MW between 200–6.5 kDa (SigmaMarker™, Sigma-Aldrich, Saint Louis, MO, USA); 2) mucus fraction from *C. aspersum* with MW > 20 kDa; B) Electrophoretic profile of a standard protein molecular marker (electrophoretic Lane 1) analyzed by ImageQuant™ TL; C) Analysis of the electrophoretic profile of mucus from *C. aspersum* with MW > 20 kDa, using ImageQuant™ TL.

A more accurate analysis of molecular masses and protein intensities in the mucus fraction with MW 20 kDa was obtained by ImageQuant™ TL v8.2.0 software, after scanning of 12% SDS-PAGE (Figure 5B,C). Based on the performed analysis, 18 protein bands were identified, most of which are with MW between 23–200 kDa. The obtained results presented in Figure 5C are in good agreement with the results of MALDI-Tof-MS analysis in the 20–80 kDa region of fresh extract from *C. aspersum* mucus [27].

2.2.3. Identification of Proteins in Mucus Fraction with MW > 20 kDa from *C. aspersum* Snail

Proteins in the mucus fraction with MW>20 kDa were determined after a performed search in the database UniProt (<https://www.uniprot.org>, 03 March 2024) for proteins in molluscs and gastropods, as well as in published data for mucus proteins in snails with MW corresponding to electrophoretic analysis (Figure 5C). Based on the conducted search, it was found that the protein presented at protein band 17.565 kDa well corresponded to mucus protein [*C. aspersum*, QEG59314] detected at 17.5 kDa in [24]. Detected proteins in the range 20–31 kDa probably belong to families of glutathione peroxidase (GPx) and glutathione transferases (GST) because several studies have confirmed the antioxidant properties (glutathione transferase activity) of *C. aspersum* mucus [25–27].

Results from the database UniProt show that in this region are detected proteins: glutathione peroxidases from *Biomphalaria glabrata* with MW 21.252 kDa (A0A2C9L5T6), MW 22.812 kDa (A0A2C9JW73) and MW 24.101 kDa (A0A2C9JBG3), peroxiredoxin-5 from *P. canaliculata* (A0A2T7NZ99 MW 20.751 kDa) and glutathione S-transferases with MW 27.978 kDa (from *P. canaliculata*, A0A2T7PWN7); with MW 27.599 kDa (from *B. glabrata*, A0A9U8DVA0); with MW 27.774 kDa (from *Haliothis rubra*, XM_025244070.1), and probable glutathione S-transferase with MW 23.092 kDa (from *Aplysia californica*, XM_035968272.1). The proteins with MW between 30–40 kDa are in good agreement with the identified proteins in the study [24], which suggests some of them are lectins and are also related to the antimicrobial properties of mucus. Recently, Cerullo et al. reported about a new protein class termed Conserved Anterior Mollusk Proteins (CAMPs) detected in the mucus of *C. aspersum* with MW<40 kDa by proteomic analysis on SDS-PAGE [32].

Some of the proteins expressed in protein bands between 48–59 kDa probably correspond to functional units or polypeptides of N-glycosylated *C. aspersum* hemocyanin resulting from proteolytic processes. The presence of different forms of hemocyanin in the mucus of land snails has been reported in several studies in recent years [21,29,30].

The protein at 84–85 kDa probably corresponded to epiphragmin, identified in the adhesive mucus secretion of land snails *H. aspersa*, *H. pomatia*, and *Cerutuella virgata* [40–43].

The electrophoretic analysis also showed proteins with MW above 100 kDa, which most likely represent different types of mucins, proteoglycans and collagen, which were confirmed in recent studies on mucus proteins of land snails *C. aspersum* [32,41], *A. fulica* [29,30] and *H. lucorum* [29] through integrative “omics” approach.

2.2.4. Characterisation of Mucus Fraction with MW > 20 kDa by Tandem Mass Spectrometrical Analyses of 12% SDS-PAGE

In order to identify some of these hypothesised proteins, the protein bands from 12% SDS-PAGE were excised from the gel. After trypsin digestion, the extracted peptides were analysed tandem mass spectrometry and bioinformatics. The amino acid sequences (AASs) of extracted peptides from each protein band were determined by MS/MS analyses because the identification of proteins only by Mascot search of the experimental peptide masses as $[M+H]^+$ did not lead to satisfactory results.

Limited proteomic information on gastropods in the NCBI database probably caused this unsuccessful protein identification. In Figure 7, the MALDI-MS/MS spectrum of peptide $[M+H]^+$ at m/z 1670.93 extracted from the protein band at 48.75 ± 1.5 kDa is presented.




Figure 7. MS/MS spectrum of peptide [M+H]⁺ at m/z 1670.93 from protein band at 48.75 kDa of fraction with MW >20 of *C. aspersum* mucus.

The determined amino acid sequence HGSPIGVPYWDWTR, shows 100% identity (E=2e-09) with hemocyanin alpha-N from *C. aspersum* (AYO86684.1).

In this way, the rest of the proteins were also determined (Table 2). Most of the presented hits demonstrate identities above 60% and E-values between 1×10⁻¹³ and 2 (Table 2, Supplementary Materials: SI 2). It is known that the lower the E-value, the more “significant” the match is, suggesting a higher probability that the sequences share a common evolutionary origin.

Table 2. AASs of peptides, determined after analysis of their MS/MS spectra. Proteins were identified after comparing AASs with a database of protein sequences by the Basic Local Alignment Search Tool (BLAST).

Band kDa	AAS of peptide	Mass [M+H] ⁺	Protein name	UniProt ID	Identities
17.5	TAAFTEDTSVVTGR	1454.63	mucus protein [<i>Cornu aspersum</i>]	QEG59314.1	86%, E=8e-05
	FTAAFTEDTSVAEGR	1601.74	mucus protein [<i>C. aspersum</i>]	QEG59314.1	100%, E=2e-09
	GNVAFTAFTEDTSVAEGR	1942.91	mucus protein [<i>C. aspersum</i>]	QEG59314.1	100%, E=4e-13
	GALNGNVAFTAFTEDTSVAEGR	2298.10	mucus protein [<i>C. aspersum</i>]	QEG59314.1	100%, E=2e-11
23.6	GSCNWPMTILMLESRL	1850.90	NADH subunit 6 [<i>Albinaria caerulea</i>]	P48922	78%, E=0.005
	QYLQITWPSR	1388.7	H-type lectin domain-cont. protein <i>B. glabrata</i>	KAI8776186.1	100%, E=0.041
26.7	VPSDDPGR	842.40	Chain A, <i>H. aspersa</i> agglutinin [<i>C. aspersum</i>]	4Q56_A	100%, E=0.003
	DITFASPYCR	1172.54	Chain A, <i>H. aspersa</i> agglutinin <i>C. aspersum</i>	4Q56_A	90%, E=1e-04
	NGGLVHPGPR	1003.54	uncharacterized protein [<i>Pomacea canaliculata</i>]	XP_025078819.1	89%, E=4.5
31.35	DWTLYVNTPLAPAR	1616.84	unnamed protein, partial [<i>C. unifasciata</i>] mucin 18b [<i>Plakobranthus ocellatus</i>]	GFO09821.1	78%, E=0.33 75%, E=27
	FCPNAQRTR	1092.54	glutathione S-transferase omega-1-like [<i>P. canaliculata</i>]	XP_025114871.1	89%, E=0.31
			[<i>Elysia marginata</i>]	GFR70608.1	89%, E=0.31
	NPVGSVPVLELDGK	1423.78	glutathione S-transferase omega-1 [<i>P. canaliculata</i>] [<i>B. glabrata</i>] containing protein [<i>B. glabrata</i>]	XP_025099831.1 KAI8762368.1	86%, E=0.013 79%, E=0.02
33.0	GPCFTPHYTNWSWLR	1965.91	unnamed protein, <i>Candidula unifasciata</i> “Bacterial protein of unknown function (HtrL_YibB)	CAG5121511.1	63%, E=4e-04
	DFLPPASLPDFAPSPRVAER	2279.18	unnamed protein product, [<i>Candidula unifasciata</i>]	CAG5136685.1	53%, E=0.34
39.1	AGYLQITWPSR	1388.72	mucus protein [<i>C. aspersum</i>] H-type lectin domain-	QEG59312.1 KAI8776186.1	100%, E=1e-08 100%, E=0.055
	ASVTGDLNSK	991.51	mucus protein [<i>C. aspersum</i>]	QEG59312.1	100%, E=8e-04
	ELGNVYRAAFTEDTSVAEGR	2298.14	mucus protein [<i>C. aspersum</i>]	QEG59314.1	77%, E=3e-08

	VGSNGAR	660.34	mucus protein [C. aspersum]	QEG59312.1	100%E=0.004
	ANVTFDLSEK	1123.56	von Willebrand factor A domain-containing protein 3B-like isoform X1 [B. glabrata]	XP_013069929.2	100%, E=0.59
			protein 3B isoform X2, [B. glabrata]	XP_013069930.2	100%, E=0.59
	LFSTASGGR	895.4632	Collagen alpha-6(VI) chain, partial [Biomphalaria pfeifferi]	KAK0040452.1	89% E=1.9
	LPLYEDPKLDVSSLR	1744.83	uncharacterized protein LOC101853718 [A. californica]	XP_012941625.1	83%, E=0.27
48.7	FDANPFFSGR	1157.59	Hemocyanin, βc chain unit D [Helix pomatia]	P12031.2	89%, E=9e-06
	HGSPIGVPYWDWTR	1670.93	Hemocyanin α N [C. aspersum]	AYO86684.1	100%, E=2e-09
	LISEATYFNSR	1300.71	hemocyanin β [C. aspersum]	AYO86685.1,	100%, E=2e-04
			βc chain unit D [H. pomatia]	P12031.2	82%, E=6e-05
	FDPNPFFSGR	1183.5	Hemocyanin, βc chain unit D [H. pomatia]	P12031.2	100%,E=3e-07
	EVFEQVEHALLAR	1540.81	Hemocyanin β [C. aspersum]	AYO86685.1	100%, E=0.006
			βc chain unit D [H. pomatia]	P12031.2	88%, E=0.050
	QYLQITWSPPR	1388.73	fibrinogen-like protein A isoform [B. glabrata]	XP_055864456.1	78%, E=1.4
52.8	TDVTSALLGARCNEG GTNTHSPLR	2470.21	unnamed protein, partial [C. unifasciata]	CAG5131631.1	70%, E=0.006
			unnamed protein C. unifasciata	CAG5131621.1	63%, E=0.26
			mucus protein [C. aspersum]	QEG59312.1	92%,E=0.001
	LTQHFNVGSNGAR	1400.70	unnamed protein C. unifasciata	CAG5131621.1	77%, E=0.094
			unnamed protein partial [C. unifasciata]	CAG5131631.1	75%, E= 0.38
	MPDYDCGCCNGSNGSYSGGGGGGGG R	2384.84	unnamed protein, partial [C.unifasciata]	CAG5126455.1	80% , E=0.23
			unnamed protein product [C. unifasciata]	CAG5131834.1	63% E=0.23
56.9	DGMSAAPQAENAFALK	1620.77	Achacin; Flags: Precursor [L. fulica]	P35903.1	71%, E=3e-04
			L-amino-acid oxidase (Escapin) A. californica	Q6IWZ0.1	63%, E=0.95
	SGFPTTSKDR	1095.54	L-amino-acid oxidase (Escapin) [A. californica	Q6IWZ0.1	100%, E=0.080
	VGGGPGVELDEFEARVELK	2088.0	Achacin; Flags: Precursor [Lissachatina fulica]	P35903.1	41% E=0.40
	AELKGDMQTYADSEKVR	2104.00	fibrillin-3, partial [Biomphalaria pfeifferi]	KAK0048148.1	48%, E=0.22
			fibrillin-3, partial [B. glabrata]	KAK6970092.1	48%, E=0.22
70.8	AKVQVIGVPDDRLLLR	1792.08	acyl-CoA synthetase family member 2, mito- chondrial-like, partial [Pomacea canaliculata]	XP_025086706.1	91%, E=0.005
			unnamed protein product, [C. unifasciata]	CAG5136482	91%, E=0.005
			uncharacterized protein LOC124113905 [H. rufescens	XP_046330350.2	100%,E=9e-04
	HGGGGGGFGGGGFGSR	1320.65	fibroin heavy chain isoform X1 [A. californica]	XP_012943828.1	81%, E=0.018
			elastin-like [Ostrea edulis] Glycine, alanine	XP_056017499.1	87%, E=0.038
			asparagine -rich protein [Haliotis asinina]	P86732.1	65%, E=0.004
84.7	YVLEDLSAADLELSR	1693.86	FMRFamide-activatedamiloride-sensitive sodium channel [C. aspersum]	Q25011.1	100%, E=0.14
	GSSVSLCVWDWAVLPR	1774.8	FMRFamide-activatedamiloride-sensitive sodium channel [C. aspersum]	Q25011.1	71%, E= 1.9
97.0	MVTSLYPGEDWAMLPR	1865.89	mucin-5AC-like, partial [Haliotis rufescens]	XP_048239711.1	56%, E= 0.15
	ETVSPGYSEGETCASITQK	2089.91	mucin-5B-like isoform X4 [H. rubra]	XP_046552239.1	62%, E= 6.7
	VFADFLHNIGASADV R	1860.92	hemocyanin β [C. aspersum]	AYO86685.1	100%, E= 2e-10
	CQVSLPYWDWAVPLR	1832.92	hemocyanin, βc chain unit G [H. pomatia]	P56823.1	100%, E= 5e-04
	LSGYDVSKVNEILK	1564.86	hemocyanin β [C. aspersum]	AYO86685.1	85%, E=8e-05
	HLWLLHCFEHDNLNGYEYDNL R	2687.25	hemocyanin β [C. aspersum]	AYO86685.1	87% E=8e-06
	ANNARLTDASHDNPFSSYT L R	2350.12	hemocyanin β [C. aspersum]	AYO86685.1	94%, E=1e-09
143.3	VGRIESES YVVKSKSK	1708.96	zinc finger protein 502-like [B. glabrata]	XP_055863608	77%, E=0.12
			184 [B. glabrata]	KAI8795828.1	77%, E=0.12
	VLTFYQSCDCVVDHCHR	2024.88	zinc finger protein 664-like [Patella vulgata]	XP_050401404.1	75%, E=1.5
	GEPGSTGPPGLK	1096.56	collagen alpha-1(IV) chain-like, partial [P. canaliculata]	XP_025114158.1	100%, E=2e-04
	NGPSGVELDEFEARVELK	1988.99	collagen alpha-1(XIII) chain - like isoform X7 [H. rubra]	XP_046573418.1	59%, E=2.5
			collagen α-4(VI) chain-like X2 [P. acuta]	XP_059154404.1	73%, E= 0.012
	FVDM DGMFSSAAGGRPEAR	2000.89	α-1(XII) chain-like [P. acuta]	XP_059163536.1	75%, E=0.26
			α-1(XII) chain-like isoform X6 [B. glabrata]	XP_055860588.1	68%, E=0.26
	RAYTDGMFSSAAGGRPEAR	1999.94	collagen α-4(VI) chain-like isoform [P. acuta]	XP_059154404.1	79%,E=0.031
			collagen α-4(VI) chain-like isoform [P. acuta]	XP_059154396.1	79%, E=0.031
	CNEG GTNTHSPLR	1385.62	collagen α-6(VI) chain-like [Physella acuta]	XP_059164377.1	89%, E=6.1
198.31	NPGYLVS K VNEILK	1573.89	mucin-2-like [P. acuta] serine/arginine repetitive matrix protein 2 [B. glabrata]	XP_059140993.1	71%, E=0.84;
				KAI8735946.1	71%, E=0.84
	DCRVRVGGLFAPSPYL FER	2279.1	mucin-17-like [Haliotis rubra]	XP_046554219.1	52%,E=0.78


FNFLPLSADALESLR	1692.90	E3 ubiquitin-protein ligase HERC2-like isoform X2 [B. glabrata]	XP_055894969.1	83%, E= 0.50
ASSGSCDFSSSTAANR	1547.64	mucin-5AC-like isoform X2 [H. rufescens]	XP_048252836.1	85%,E= 0.45
		mucin-5AC-like isoform X1 [H. rufescens]	XP_048252834.1	85%,E= 0.45
GCAGCPQAGSK	978.41	fibrillin-1-like [B. glabrata]	XP_055888733.1	89%, E=2.9

The results shown in Table 2 confirm the presence of mucus protein [QEG59314, from *C. aspersum*]; NADH dehydrogenase subunit 6 [*Albinaria caerulea*]; glutathione S-transferase omega-1 [*P. canaliculata*]; H-type lectins included *H. aspersa* agglutinin, mucus protein with MW 39.115 kDa named [QEG59312 from *C. aspersum*] which probably is homology von Willebrand factor A domain-containing protein 3B; Functional unit β c-d of *C. aspersum* hemocyanin, L-amino-acid oxidase-like protein (as Achacin from *L. fulica*), FMRFamide-activated amiloride-sensitive sodium channel, zinc finger protein, elastin-like protein, several typs collagen (collagen alpha-1, collagen α -4, collagen alpha-6) and mucins (mucin-5AC, mucin-5B, mucin-2, and mucin-17-like proteins). Most of the detected proteins can be associated with antimicrobial and antioxidant properties of this protein mucus fraction.

2.3. Antimicrobial Effect of Two Fractions Isolated from *C. aspersum* Mucus

The antibacterial activity of the investigated peptides and polypeptides in both mucus fractions with MW < 20 kDa and MW > 20 kDa from the snail *C. aspersum* was determined against different bacterial strains by minimum inhibitory concentration (MIC) analysis. Two strains of gram-positive pathogenic bacterial isolates (*Bacillus cereus* 1085, *Propionibacterium acnes* 1897) and three strains of gram-negative ones (*Salmonella enterica* 8691, *Enterococcus faecalis* 3915, *Enterococcus faecium* 8754) were used as test microorganisms. The obtained results showed a different degree of effectiveness of the investigated substances.

The MIC values presented in Figure 8a,b show a higher antimicrobial potential of the fraction with MW > 20 kDa of *C. aspersum* mucus compared to the fraction with MW < 20 kDa, inhibiting at concentrations of 32–128 μ g/mL more of 90% of the microbial growth of Gram+ pathogenic bacterial isolates *Bacillus cereus* 1085 and *Propionibacterium acnes* 1897. Furthermore, the effect against Gram+ microorganisms of the bioactive compounds in this fraction was observed even at low concentrations (2–4 μ g/mL), having values higher than the IC₅₀.







Figure 8. Antibacterial activity of two mucus fractions from *C. aspersum* snail with MW < 20 kDa (a1, a2,) and MW > 20 kDa (b1, b2) against selected Gram-positive pathogenic strains. As a positive control the antibiotic Vancomycin (VCM) is used. The control (C) represents untreated cells. Treatments were carried out with concentrated (Conc) and diluted fractions of snail mucus.

The antimicrobial activity of the mucus fraction with MW >20 kDa against Gram-negative bacteria - *Salmonella enterica* 8691, *Enterococcus faecalis* 3915, *Enterococcus faecium* 8754 is also well expressed. Even at concentrations of 8 µg/mL, more than 70% inhibition of bacterial growth was achieved (Figure 9a,b). Analysis of the peptide fraction with MW <20 kDa from *C. aspersum* mucus also showed the presence of a well-expressed antibacterial effect (Figure 9a). Still, the reported IC₅₀ values were lower than those of the protein fraction with MW>20 kDa. They range between IC₅₀–IC₈₀ against Gram+ bacteria and have a maximum IC₇₀ against Gram– strains at the highest mucus concentrations tested. The weakest effect was reported for *Salmonella enterica* 8691. Interestingly, the antimicrobial activity of both investigated fractions of *C. aspersum* mucus is comparable to that of the antibiotic vancomycin, but only when higher concentrations are used. When peptide and protein mucus fractions are added to the culture medium in concentrations 8 µg/mL, their effect is greatly reduced.






Figure 9. Antibacterial activity of tow mucus fractions from *C. aspersum* snail with MW < 20 kDa (a) and MW > 20 kDa (b) against selected Gram (-) pathogenic strains. As a positive control the antibiotic Vancomycin (VCM) is used. The control (C) represents untreated cells. Treatments were carried out with concentrated (Conc) and diluted fractions of snail mucus.

2.4. Studying the in Vitro and in Vivo Effects of Snail Mucus on Eukaryotic Cell

The yeast *Saccharomyces cerevisiae* has been used as a model system for eukaryotic cell biology to assess the effect of both isolated bioactive fractions of *C. aspersum* mucus on eukaryotic cell metabolism. A time-kill kinetics test was performed, which revealed that the viability of mucus-treated *S. cerevisiae* cells was not significantly different from the not-treated ones (Figure 10).




Figure 10. Effect of *C. aspersum* mucus fraction with MW<20 kD (a) and MW>20 kD (b) on *S. cerevisiae* NBMCC 584 growth.

Even at the 24h hour of cultivation, some growth stimulation effect has been observed, showing a 3–30% increase in the cellular biomass when snail mucus has been added to the nutrient media. Moreover, the observed improvement in the cell growth did not depend significantly on either the added snail mucus concentration or the bioactive fraction type—with MW<20 kD or with MW>20 kDa.

Next, the possible cytotoxic effect of the isolated bioactive snail mucus fractions on the eukaryotic cell has been studied. The *S. cerevisiae* cells were treated with concentrations of both fractions exceeding those used in characterizing their antibacterial activity. Then, the alternation in the levels of intracellularly generated ROS and carbonylated proteins was evaluated (Figure 11). It was revealed that in the cells treated with 256 µg/mL snail mucus either with MW < 20 kDa or with MW>20 kDa, ROS generation was decreased by 29% to 38%, respectively, compared to the untreated cells (Figure 11a). Simultaneously, the intracellular levels of oxidized proteins were not significantly different between treated and untreated cells, ranging between 18.37 ± 0.98 and 19.06 ± 0.87 µmol/mg of protein (Figure 11b).





Figure 11. Intracellular ROS (a) and carbonylated proteins' (b) levels in *S. cerevisiae* NBMCC 584 cells grown in the presence of *Cornu aspersum* mucus fractions with MW<20 kD and MW>20 kDa.

To evaluate the possible mechanism involved in the growth-stimulating and cytoprotective effect of *C. aspersum* snail extracts on *S. cerevisiae* eukaryotic cells, intracellular GSH levels and TAC were evaluated (Figure 12). It was shown that exposure to both mucus fractions with MW<20 kD and MW>20 kD leads to an increase in the cytoplasmic GSH level of 35% and 25%, respectively (Figure 12a). The same tendency was observed when TAC was assessed. The exposure of *S. cerevisiae* cells to the action of snail BACs causes an increase in the total antioxidant capacity of the cell (Figure 12b).






Figure 12. Effect of *C. aspersum* mucus fractions with MW<20 kD and MW>20 kD on *S. cerevisiae* NBIMCC 584 cellular reduced glutathione levels (GSH) (a) and total antioxidant capacity (TAC) (b).

3. Discussion

The biologically active substances with antibacterial action from natural sources provide the prospect of obtaining a new type of antimicrobial agents—with reduced or even absent toxicity towards people but highly effective towards inhibition of the pathogenic microorganisms [18]. Most Gastropods have high potential as sources of antimicrobial peptides and proteins. Several studies demonstrated the presence of highly effective peptides and proteins in the mucus of terrestrial snails [19–24,30] as well as freshwater [41] and marine snails [17,18,45]. The mucus secretions of snails and slugs play a pivotal role in the survival and interaction of the animals with the environment. It is crucial to continue identifying the natural antimicrobial potential of snail mucus because the rise of drug-resistant bacterial species continues to develop. To date, there are still few studies on the antimicrobial properties of the mucus of terrestrial molluscs and most of them have focused on the land snail, *A. fulica* [24].

The data obtained in the present study showed a strong antibacterial effect of the two fractions from the mucus *C. aspersum* against 2 Gram-positive pathogenic bacterial stains (*B. cereus* 1085, *P. acnes* 1897) and 3 strains of Gram-negative ones (*S. enterica* 8691, *E. faecalis* 3915, *E. faecium* 8754). Results of the in vitro study showed that high concentrations (128 µg/mL and 64 µg/mL) of both fractions with MW < 20 kDa and MW > 20 kDa exhibited antimicrobial activity against tested pathogenic bacterial strains comparable to antibiotic VCM.

The obtained data are in accordance with the results of other researchers, who prove the presence of specific oligo and polypeptides with antibacterial action in the mucus of land snails [19–21,23,24,37]. Our previous studies showed that the fraction with MW < 20 kDa shows strong antibacterial activity against *P. aureofaciens* AP9 in deep inoculation of the bacterium, while the fraction with MW between 10–30 kDa exhibits the highest antibacterial activity using surface inoculation of bacterial strain *E. coli* NBIMCC 8785 [19]. A protein fraction with Mw >20 kDa was also found to be most effective against the bacterial strain *C. perfringens* in deep anaerobic cultivation [19]. The observed differences in the antimicrobial activities against the tested pathogens are due to the difference in the active components of the two fractions.

The characterization of both fractions showed that their antimicrobial properties are due to different biocomponents, mainly antimicrobial peptides and polypeptides in the fraction with MW < 20 kDa and proteins with potential antibacterial properties in the fraction with MW > 20 kDa.

The peptide fraction with MW<20 kDa from *C. aspersum* mucus contains mostly various peptides < 3 kD with antimicrobial and antioxidant properties as some metabolites such as amino acids, allantoin, glycolic acid, γGSH and others [46]. In the current study, 16 newly antimicrobial peptides (shown in Table 1) were identified, as well as several peptides with higher molecular weight between 3–10 kDa and some proteins detected as [M+H]⁺ at m/z between 10–20 kDa. The identified peptides (Table 1) contain high levels of glycine, leucine, valine, and proline amino acid residues, as well as the presence of tryptophan, aspartic acid, phenylalanine, and arginine, which are associated with their antimicrobial activity and antioxidant properties. Amino acid sequence alignment comparison

of *C. aspersum* mucus peptides by (<http://www.campsign.bicnirrh.res.in/blast.php>) CAMPSing software revealed high identity (more than 70%) with known AMPs (SI1). The structural characteristics of the peptides with the highest prognostic antibacterial and antifungal activity (Nos 17, 18, 21, 22, 23, Table 1) show high levels of glycine, leucine, valine, and proline residues, indicating that they belong to a new class of antimicrobial peptides, rich in Gly and Gly/Leu, which demonstrate broad-spectrum antibacterial activity [47].

Previous studies have also shown the presence of peptides with similar amino acid sequences revealed homology with mostly Leptoglycin, Acanthoscurrin and Ctenidin [19,36–38]. In addition, most peptides with high predictive therapeutic values are cationic and/or neutral (with one or two positively charged residues that are neutralized with negatively charged ones). Most of the identified peptides (Table 1) are hydrophobic, which is a known prerequisite for their antimicrobial activity because hydrophobicity not only modulates the peptide-membrane interaction but also affects cellular selectivity and is positively correlated with cytotoxic activity [44,48]. AMPs are known to kill microbes through mechanisms that primarily involve interactions between the charged amino acid residues of the peptide and components of the bacterial membranes of the target cells. There are several mechanism models to explain the action of these peptides, including the toroidal pore model, the barrel model, and membrane interaction according to the Shai–Huang–Matsuzaki carpet model [48–51]. These interactions can lead to a number of effects, including membrane permeabilization, depolarization, leakage or lysis, leading to cell death.

In the current study, in a fraction with MW <20 kDa, some peptides with higher molecular masses between 10–20 kDa were identified, which are in good agreement with similar proteins in snail mucus of *C. aspersum* [24,33], *Helix pomatia* [34] and *A. fulica* [35] and may also contribute to the antibacterial activity against the tested bacterial pathogens. For example, polypeptide determined at 12.464 kDa (Figure 2) is probably a lectin previously found in a study by Pietrzyk et al., in the mucus of *C. aspersum* [33]. A similar protein with biological activity against *Streptococcus mutans* and *Aggregatibacter actinomycetemcomitans* was also found in *A. fulica* mucus with 11.45 kDa with [52]. The protein detected by us at m/z 18.005 kDa in a fraction with MW < 20 kDa using MALDI-MS analysis (Figure 2) probably corresponds to the anti-*Pseudomonas aeruginosa* protein (MW 17.5 kDa) described in a study by Pitt et al. [24].

Several studies have shown that mucus from *C. aspersum* snail also demonstrates antimicrobial activity due to one or more proteins with molecular masses between 30 and 100 kDa [19,20,24,52]. Based on the results of the electrophoretic analysis and proteomic analysis on SDS-PAGE of a fraction with MW > 20 kDa, a high homology was found with some proteins with potential antibacterial activity. Surprisingly, a protein at 17.5 kDa was detected on SDS-PAGE analysis of the fraction with MW > 20 kDa. Alignment of AASs obtained by MALDI-TOF-MS/MS showed homology to mucus protein from *C. aspersum* snail (ID QEG59314.1), identified by Pitt et al., as a lectin with potential antimicrobial activity against strains of *Ps. aeruginosa*. Some lectins have pathogen-recognition receptor properties, which may contribute to their antimicrobial activity. Natural lectins have powerful antibacterial properties because they bind to carbohydrates on microbial surfaces [53].

The results of the proteomic analysis show that peptides extracted from the protein band at 26 kDa are homologous on H-type lectin from *B. glabrata* and agglutinin from *H. aspersa* (HAA) and *H. pomatia* (HPA), which also play a role in the defense of the snail against pathogens. H-type lectins represent a new group of lectins that have been identified in invertebrates. In snails, H-type lectins (eg, HPA, HAA) protect fertilized eggs from bacteria because they are secreted by snail protein glands as a component of the perivitelline fluid [54,55]. Lectins are involved in many biological processes, including cell recognition, viral and bacterial pathogenesis, and inflammation [54]. Some studies have shown that high molecular weight lectin isolated from the mucus of the giant African snail *A. fulica* induces agglutination of Gram⁺ and Gram[−] bacteria, although it does not inhibit bacterial growth [56]. In addition, H-type lectins recognize glycans present in the cell wall of pathogenic bacteria, for example group C *Streptococcus* sp. Agglutinins are glycoproteins in nature and play a fundamental role in the innate immune responses in invertebrates [57].

AASs of several peptides extracted from the protein band at 39.115 kDa (Table 3) show high homology with antibacterial mucus protein with MW ~37.5 kDa (QEG59312.1, *C. aspersum*) named 'Aspernin', active against different strains of *Ps. aeruginosa* [24]. According Pitt et al., the protein 'Aspernin' shares homology with proteins in another species of snail—*Biomphalaria glabrata*, such as H-type lectin domain-containing protein [*B. glabrata*] [24]. Our results also showed that some peptides derived from this protein band matched domains of the von Willebrand factor A superfamily. The proteins with MW between 30 and 40 kDa found in the fraction with MW > 20 kDa are in full agreement with the recently detected proteins by Pitt et al. that suggest that these proteins are lectins and are also related to the antimicrobial properties of the mucus [24].

Another identified protein in mucus fraction with MW>20 kDa with antibacterial activity is hemocyanins. Our results (presented in Figure 5 and Table 2) revealed that the intensive band in the range of 48.75±1.5 kDa and 97.0±1 kDa is composed of proteins demonstrating high homology to hemocyanin functional units and subunits. The high protein expression of different forms of hemocyanin can explain observed antibacterial activity against tested bacterial pathogens (Figure 8b1,b2 and Figure 9b1,b2,b3). Previous studies have also demonstrated that molluscan hemocyanin possesses antibiotic activity [58–60], which supports our hypothesis. Interest in hemocyanin as a bioactive molecule against pathogenic microorganisms is relatively recent [58,61,62]. Information about the antibiofilm and antiviral activity of hemocyanin from land snails is still very scarce. [21]. Moreover, hemocyanin-derived polypeptides (detected at 40, 60 and 80 kDa) with possible antimicrobial properties were previously reported by Suárez et al. [21]. Furthermore, Dolashka et al., 2016 reported the antimicrobial activity of the β c-HaH structural subunit of *H. aspersa* (also named *C. aspersum*), which demonstrated strong selective antimicrobial activity against *S. aureus*, *Streptococcus epidermidis* and *Escherichia coli*, while *Ps. aeruginosa* and *E. faecium* developed unconditionally with his presence [16]. Therefore, the observed antibacterial activity of fractions with MW> 20 kDa against *B. cereus* 1085, *P. acnes* 1897, *S. enterica* 8691, *E. faecalis* 3915, and *E. faecium* 8754, cannot be fully explained only by the identification of hemocyanin.

In addition, on the protein band at 52.89±1.0 kDa, another protein was found homological with the *C. aspersum* mucus protein (QEG59312.1) and an unnamed protein from *Candidula unifasciata* snail (CAG5131631.1 and CAG5131621.1). This protein is likely related to the antimicrobial activity of fraction with MW > 20 kDa. The study by Pitt et al., [24] also mentioned a protein with MW at ~50 kDa with potential antimicrobial activity against *Ps. aeruginosa*. Furthermore, we found that the protein detected at the range 56.94–59.04 kDa shared homology with proteins with L-amino acid oxidase activity, such as Achacin, which is established as an antibacterial N-glycosylated protein in the mucus of snails *L. fulica*, *A. fulica*. Several studies have associated the broad spectrum of antimicrobial properties of the mucus of the giant African snail *A. fulica* against Gram⁺ bacteria (*Bacillus subtilis* and *Staphylococcus aureus*), and Gram[−] strains (*Escherichia coli* and *Ps. aeruginosa*) mainly with the presence of Achacin.

In another study [21], it was presented that the activity against the biofilm-forming bacteria *S. aureus* was found to be mainly due to the action of proteins hemocyanin and 'Achacin' and their fragments resulting from proteolysis processes. Indeed, Achacin, in addition to inhibiting bacterial growth, also appears to attack bacterial plasma membranes [31]. It was found that the antibacterial activity of Achacin depends on the production of H₂O₂, which is obtained from the oxidative deamination reaction. These data indicate that Achacin can also attack pathogens during other growth phases by increasing the local H₂O₂ concentration to not harm neighbouring host cells [30,63].

Extracellular matrix proteins constitute 40–50% of the mucus proteins of *C. aspersum* [30]. Our results have proven the presence of homologous proteins on mucin-5AC, mucin-5B, mucin-2, and mucin 17 like proteins, as well as collagens. Mucin proteins, included in snail mucus, can play roles for several biological functions, including adhesion, lubrication, and microbial protection [64,65]. Mucins are among the largest macromolecules, characterized by protein core and branching glycan chain. The structural diversity of mucins allows for their extensive biological diversity and unique physical characteristics. A tandem repeat domain located in the centre of the protein backbone, rich in serine, threonine, and proline, serves as an anchor for glycosylation. Mucin glycans are

predominantly O-linked, but minor amounts of N-linked glycans also can be present [64,66]. It appears that mucins, which are an important component of snail mucus, play an important role as the first line of defense against bacterial infections. However, how the glycoprotein mucin—which makes up the mucus—interacts with the bacteria is still not fully understood [67]. For example, the MUC2 mucin established in the mucus fraction, but also found in the human colon, is capable of aggregating Gram⁺ bacteria such as *Bacillus subtilis* and *E. faecalis* by binding to peptidoglycan present in the cell wall, thereby inhibiting epithelial cell penetration. Furthermore, both mucins MUC5AC and MUC5B have been shown to inhibit up to 85% *Pseudomonas aeruginosa* isolated from sputum of patients with chronic infection [67]. Antimicrobial potentials of mucus mucins from different species of giant African land snails on some typed culture pathogenic bacteria were studied by Okeniyi et al., 2022 [68]. It was found that snail mucus extract had antimicrobial effects on Gram⁺ and Gram[−] bacteria, but mucus mucins seem to lose its antibacterial potential with time [68]. *A. marginata*'s mucus secretions had a stronger antibacterial activity against *B. subtilis* when compared to mucus from *A. achatina* and *A. fulica* [22].

Moreover, the performed study demonstrates that both isolated *C. aspersum* mucus fractions with MW < 20 kD and MW > 20 kDa are not cytotoxic to eukaryotic cells but are characterized by growth-promoting potential. Bearing in mind that microorganisms and various Mollusca frequently form symbiotic relationships that are crucial to the ecology and evolution of species [69], it could be suggested that mucus from *C. aspersum* is used from *S. cerevisiae* as a supplementary substrate for its growth. Adding both mucus fractions to the nutrient media further leads to a substantial reduction in ROS levels. ROS generated during cell growth are involved in the roughly 60 distinct pathways that lead to protein oxidation, which includes carbonylation causing unbalanced cellular proteome and malfunctions [70]. Obtained results suggested that *C. aspersum* mucus possesses ROS scavenging properties, which automatically reflects their ability to reduce the level of carbonylated proteins in the eukaryotic organisms while combating the pathogenic bacterial strains. Thus, the two isolated bioactive fractions from *C. aspersum* can not only be used effectively to treat antibiotic-resistant pathogens, but their administration also has additional beneficial effects related to the reduction of oxidative stress in the host organism's cells. In fact, other authors confirmed the radical scavenging activity of snail mucus, showing that *P. canaliculata* and *L. fulica* mucus have pro-oxidant capacity [71]. Furthermore, the same authors observed that the *L. fulica* mucus exhibited higher antioxidant capacity similar to those we found for the *C. aspersum* mucus low and high molecular weight mucus fractions. According to Wang et al. (2010) [72], low molecular weight components found in snail mucus, including uronic acid, phenolic compounds, vitamins C and E, and uric acid, determine their antioxidant qualities.

The specific characteristics of the many mucus peptides, such as their hydrophobicity, molecular mass, and AAS, are also related to its antioxidant capacity [73]. Several studies in recent years have confirmed the antioxidant properties of a *C. aspersum* mucus, and a fraction with MW > 20 kDa included antioxidant superoxide dismutase and glutathione transferase activity [25–27]. Antioxidants are substances that can protect cells from damage caused by unstable molecules known as free radicals or reactive oxygen species.

The study of the chemical composition of *C. aspersum* mucus fractions further confirmed that its antibacterial and cytoprotective properties are probably due to the complex action of the specific compounds found in it. The presence of specific innate antimicrobial peptides, as well as of antibacterial proteins such as mucus protein QEG59314.1 and QEG59312.1, different forms of hemocyanin, which serve as a precursor of broad-spectrum antimicrobial agents and microbial agglutination, determines the high antibacterial activity of the isolated bioactive fractions [59]. The demonstrated strong overall antioxidant activity in treated eukaryotic cells could be attributed to the role of both glutathione S-transferase and NADH dehydrogenase-like proteins found in the snail mucus.

Our study reveals that *C. aspersum* mucus has the potential to act as a source of antibacterial agents against bacterial pathogens *B. cereus* 1085, *P. acnes* 1897, *S. enterica* 8691, *E. faecalis* 3915, *E. faecium* 8754, for the first time. Both mucus fractions, demonstrated antimicrobial activity and

antioxidant properties, may become an alternative agent to expensive synthetic antibacterial compounds. Application of a fraction with MW > 20 kDa showed promising antimicrobial activity comparable to Vancomycin and without adverse side effects. However, further studies are needed to use mucus secretion in solving the problem of antibiotic resistance in bacterial pathogens.

4. Materials and Methods

4.1. Preparation of Mucus Extract

The mucus extract was prepared from crude mucus collected from snail *C. aspersum*, grown in Bulgarian eco-farms using patented technology, so the snails survived without disturbing their biological functions [19]. After several filtration steps (also an object of patented technology), the native mucus extract was obtained. The protein concentration in the native mucus extract was determined by Bradford assay [74]. After ultrafiltration using a membrane filter from 20 kDa, the crude mucus extract was separated into two fractions: a peptide fraction with MW below 20 kDa and a fraction containing compounds with MW above 20 kDa.

The peptide fraction with MW below 20 kDa was additionally separated into three fractions using Amicon® Ultra-15 centrifugal tube filters with 3 and 10 kDa membranes. Finally, the following samples were obtained: Sample 1 — a fraction with compounds of MW <3 kDa; Sample 2 — a fraction with compounds of MW 3–10 kDa; Sample 3 fraction with compounds of Mw 10–200 kDa

4.2. HPLC Purification of Peptides from the Fraction Below 20 kDa

Reverse-phase high-performance liquid chromatography (RP-HPLC) on ZURA®; HPLC system (KNAUER, Berlin, Germany) was used to purify mucus fraction with MW below 20 kDa after lyophilization on a Nucleosil C18 column equilibrated with 0.1% trifluoroacetic acid (TFA, v/v) (solution A). Elution was performed by a gradient of water–acetonitrile formed by solutions A (0.1% TFA/water) and solution B (100% acetonitrile in 0.1% TFA (v/v)) at a flow rate of 1.0 mL/min, for 70 min as follows: to 10 min., A 100%; 11–20 min., A 90%; 21–50 min., A 40%; 51–60 min., A 0%; 61–63 min., A 0%; and 64–70 min., A 100%. Ultraviolet absorption was monitored at 216 nm.

The eluted fractions were collected and dried by vacuum concentration Speed-110 vac. The fractions were reconstituted in Milli Q water containing 0.10% TFA (v/v).

4.3. Molecular Mass Analysis and De Novo Sequencing of Peptides by Mass Spectrometry

The isolated peptide fraction with MW <3 kDa (Sample 1) was lyophilized and analysed by MALDI-TOF-TOF mass spectrometry on an Autoflex™ III. High Performance MALDI-TOF& TOF/TOF System (Bruker Daltonics, Bremen, Germany), which uses a 200 Hz frequency-tripled Nd–YAG laser operating at a wavelength of 355 nm. Analysis was carried out after mixing 2.0 µL of the sample with 2.0 µL of matrix solution (7 mg/mL of α -cyano-4-hydroxycinnamic acid (CHCA) in 50% ACN containing 0.1% TFA), but only 1.0 µL of the mixture was spotted on a stainless steel 192-well target plate. The samples were allowed to dry at room temperature before being analyzed. A total of 3500 shots were acquired in the MS mode, and a collision energy of 4200 was applied. The mixture of angiotensin I, Glu-1-fibrinopeptide B, ACTH (1–17), and ACTH was used for calibration of the mass spectrometer.

The MS/MS spectra were carried out in reflector mode with external calibration using fragments of Glu-fibrinopeptide B. Amino acid sequences of peptides were identified by precursor ion fragmentation using MALDI-MS/MS analysis.

4.4. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)

The eluted intravenous immunoglobulins were analyzed by 1D-sodium dodecyl sulphate-polyacrylamide gel electrophoresis (1D-SDS-PAGE) using 5% stacking gel and 12% resolving gel, according to the Laemmli method with modifications [75]. The samples were dissolved in Laemmli sample buffer containing 10 mM DTT as reducing agent. Staining Coomassie Brilliant Blue G-250

buffer was used for the visualization of proteins on the gel as well as a protein standard marker—mixture of proteins with molecular weight from 6.5 kDa to 200 kDa (SigmaMarker™, Sigma-Aldrich, Saint Louis, MO, USA).

4.5. Image Analysis of 10% SDS-PAGE by ImageQuant™ TL v8.2.0 Software

The obtained polyacrylamide gel (PAG) was captured on an Image Scanner III (GE Healthcare) and the image was opened within the ‘1D gel analysis’ utility of the Image Quant TL v8.2 software (GE Healthcare Bio-Sciences AB, Uppsala Sweden), which is highly automated and easy-to-use image analysis software. The background was performed through the “image rectangle” setting to compensate for the intensity of the image background. All bands were identified manually, including those in the standard protein marker, with a pen tool, as the bandwidth was fixed at 54 pixels. The molecular weight analysis of each band was performed using the protein data standard SigmaMarker™ (Sigma-Aldrich, Saint Louis, MO, USA) in the range of 6500–200,000 Da. Automatically, horizontal bands were drawn to the individual bands of the MW marker and calculated with the cubic curve spline.

Based on the pre-calculated amount of bands at the marker, the amount of bands tested is determined [76].

4.6. Tryptic In-Gel Digestion and Peptide Extraction

Protease digestion was run according to the work of Rosenfeld et al. with a slight modification [18]. The target protein bands excised from the SDS-PAGE gels were washed twice with a 150 µL mixture of 50% acetonitrile (ACN) and 200 mM NH₄HCO₃ each for 20 min at 30 °C to decolorize, as described previously in [77]. The digestion of proteins in gel was carried out with porcine trypsin (Promega, Madison, WI, USA). After drying the decolourized gels in the speed vac concentrator, a volume of 10 µL digestion buffer (50 mM ammonium bicarbonate, pH 7.8, containing modified trypsin) was added to them, and the Eppendorf tubes were kept on ice for 45 min to allow the gel pieces to be completely soaked with the protease solution. Digestion was performed overnight at 37 °C, the supernatants were recovered, and the resulting peptides were extracted twice with 35 µL of 60% ACN/0.1% HCOOH. The extracts were pooled and dried in the speed vac concentrator.

4.7. Antibacterial Activity Assay

The antibacterial activity of the two bioactive fractions from *C. aspersum* was tested against 2 Gram-positive and 3 Gram-negative pathogenic bacteria listed below. It has been determined according to the procedure for the Minimum Inhibitory Concentrations (MICs) using the broth microdilution method according to Clinical Laboratory and Standards (CLSI) guidelines [78]. Briefly, the bacterial suspension cultured to the logarithmic phase was diluted to 0.5 McFarland Standard (approximately 1.5×10⁸ CFU/mL) and then diluted 150 times to 1×10⁶ CFU/mL using nutrient media. A 50 µL volume of undiluted and serial twofold dilutions of BACs with the Mueller Hinton broth (and Brain Heart Infusion broth for *P. acnes*) was dispensed in 96-well microtiter plates. Subsequently, an equal volume of adjusted inoculum (1×10⁶ CFU/mL) was added to each well of the Microtiter plates up to a final volume of 100 µL. The nutrient media with bacterial culture without bioactive fractions was used as a negative control, and in the positive control, bioactive fractions were replaced by the glycopeptide antibiotic vancomycin (VCM)—(stock solution 40 mg/mL). The MIC value is accepted as the lowest concentration of snail BACs at which bacterial growth is completely inhibited.

Bacteria strain	Causative agents
<i>Bacillus cereus</i> NBIMCC 1085	Foodborne disease
<i>Propionibacterium acnes</i> DSM 1897	Skin condition of acne, chronic endophthalmitis, corneal ulcers, sarcoidosis, etc.
<i>Salmonella enterica</i> NBIMCC 8691	Salmonellosis

<i>Enterococcus faecalis</i> NBIMCC 3915	Endocarditis, sepsis, urinary tract infections (UTIs), meningitis, etc.
<i>Enterococcus faecium</i> NBIMMCC 8754	Bloodstream infections, urinary tract infections (UTIs), and wound infections associated with catheters or surgery are the most common infections.

4.8. In vivo and In Vitro Effect on Eukaryotic Cell

The effect of both isolated fractions from the mucus of *C. aspersum* on the eukaryotic cell was evaluated using *Saccharomyces cerevisiae* as a model organism.

4.8.1. Cell Treatment and Viability Assay

Saccharomyces cerevisiae NBIMCC 584 were obtained from the National Bank for Industrial Microorganisms and Cell Cultures (Sofia, Bulgaria). The cells were cultured in a standard YPD medium containing 2% glucose, 1% yeast extract, and 1% peptone (pH 6.5) at 30 °C. A time-kill kinetics test has been performed, adding various concentrations of mucus fractions with MW<20 kD and MW>20 kD to the growth media (0, 64, 128, 256 µg/mL). Yeast growth was quantified after incubation for 0, 3, 6, 12 and 24 h. Absorbance was measured at 600 nm using a microplate reader.

For in vitro experiments, 1g *S. cerevisiae* biomass was treated with both mucus fractions at a final concentration of 256 µg/mL for 1 h at 25 °C, washed twice with distilled water and subjected to mechanical disruption according to the procedure described by [79]. Obtained cell-free extracts were further used for the biochemical analysis.

4.8.2. Measurement of the Mucus Cytotoxic Effect

The cytotoxic effects of the two mucus extracts were evaluated by measuring the alternations in the intracellular levels of ROS and carbonylated proteins. The generation of ROS in the *S. cerevisiae* cells was examined using the nitroblue tetrazolium test (NBT) method described by Kostova et al. (2008) [80]. The levels of oxidized proteins were assessed following the procedure of Mesquita et al. (2014) [81].

4.8.3. Determination of Cytoprotective Effect

The reduced glutathione (GSH) levels in the cells were measured using Zhang’s method (2000) [82]. The Total Antioxidant Capacity (TAC) has been evaluated using Kumaran and Karunakaran’s (2006) phosphomolybdenum method [83].

5. Conclusions

In summary, our study reveals for the first time that *C. aspersum* mucus has the potential to act as a source of antibacterial agents against the bacterial pathogens—*Bacillus cereus* 1085, *Propionibacterium acnes* 1897, *Salmonella enterica* 8691, *Enterococcus faecalis* 3915 and *Enterococcus faecium* 8754. Both mucus fractions with MW <20 and MW>20 kDa, applied in the highest concentration of 128 µg/mL, demonstrated antimicrobial activity against tested pathogens that were comparable to Vancomycin. Also, the mucus fraction with MW>20 kDa showed promising activity even in concentrations between 8–2µg/mL. Furthermore, both mucus fractions are non-cytotoxic to eukaryotic cells and are characterized by growth-promoting potential and antioxidant properties. The study showed 16 novel peptides with MW between 1000–2900 Da identified by *de novo* sequencing in a mucus fraction with MW <20 kDa, with potential antibacterial activity. Based on the results of electrophoretic and proteome analysis of mucus fraction with MW >20 kDa, some proteins have been identified that demonstrate high homology to proteins with antibacterial potential, such as mucus protein called Aspernin, H-type lectins, hemocyanin, L-amino acid oxidase-like protein as well as mucins (mucin-5AC, mucin-5B, mucin-2 and mucin-17-like proteins) with MW > 100 kDa. Additionally, homology to glutathione S-transferase and NADH dehydrogenase was found.

These results present *C. aspersum* mucilage as a potent non-cytotoxic antibacterial agent—an alternative to conventional antibiotics while avoiding the development of antibiotic resistance.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Supplementary Information 1 (SI1): An alignment of amino acid sequences of some identified peptides from *C. aspersum* mucus with known antimicrobial peptides with data base AMPs by CAMPSing, Matrix: BLOSUM 80 (<http://www.campsign.bicnirrh.res.in/blast.php>) and with proteins by BLAST (<https://blast.ncbi.nlm.nih.gov>); Supplementary Information 2 (SI2): An alignment of amino acid sequences of some identified peptides from protein bands of mucus fraction with MW>20 kDa with known proteins in Gastropoda (taxid:6448), land snail land snails (taxid:6527), and Mollusca (taxid:6447) with database non-redundant protein sequences (nr) and UniProtKB/Swiss-Prot, sequences algorithm blastp (protein-protein BLAST), filtered to match records with percent identity between 50% and 100% (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Author Contributions: For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, X.X. and Y.Y.; methodology, X.X.; software, X.X.; validation, X.X., Y.Y. and Z.Z.; formal analysis, X.X.; investigation, X.X.; resources, X.X.; data curation, X.X.; writing—original draft preparation, X.X.; writing—review and editing, X.X.; visualization, X.X.; supervision, X.X.; project administration, X.X.; funding acquisition, Y.Y. All authors have read and agreed to the published version of the manuscript.” Please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

Funding: This research was carried out with the support of the project KP-06 PN61-8/2022 funded by the Bulgarian National Science Fund.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article and supplementary material.

Acknowledgments: Project BG05M2OP001-1.002-0019: ‘Clean Technologies for Sustainable Environment—Waters, Waste, Energy for a Circular Economy’.

Conflicts of Interest: The authors declare no conflicts of interest. The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Garvey, M. Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens. *Infect. Dis. Rep.* **2023**, *15*, 454–469. <https://doi.org/10.3390/idr15040046>.
2. Hernando-Amado, S.; Coque, T.M.; Baquero, F.; Martínez, J.L. Antibiotic Resistance: Moving From Individual Health Norms to Social Norms in One Health and Global Health. *Front. Microbiol.* **2020**, *11*, 1914. <https://doi.org/10.3389/fmicb.2020.01914>.
3. Final Report DRUG-RESISTANT INFECTIONS A Threat to Our Economic Future, March 2017, Jonas and World Bank Group Team, **2017**.
4. Walsh, T.R.; Gales, A.C.; Laxminarayan, R.; Dodd, P.C. Antimicrobial Resistance: Addressing a Global Threat to Humanity. *PLoS Med* **2023**, *20*(7), e1004264. <https://doi.org/10.1371/journal.pmed.1004264>.
5. Huan, Y.; Kong, Q.; Mou, H.; Yi, H. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. *Front. Microbiol.* **2020**, *11*, 582779. <https://doi.org/10.3389/fmicb.2020.582779>.
6. Orlek, A.; Anjum, M.F.; Mather, A.E.; Stoesser, N.; Walker, A.S. Factors associated with plasmid antibiotic resistance gene carriage revealed using large-scale multivariable analysis. *Sci. Rep.* **2023**, *13*(1), 2500. <https://doi.org/10.1038/s41598-023-29530-y>.
7. Akram, F.; Imtiaz, M.; ul Haq, I. Emergent crisis of antibiotic resistance: A silent pandemic threat to 21st century. *Microbial Pathogenesis* **2023**, *174*, 105923. <https://doi.org/10.1016/j.micpath.2022.105923>.
8. Aisenbrey, C.; Bechinger, B. Molecular packing of amphipathic peptides on the surface of lipid membranes. *Langmuir* **2014**, *30*(34), 10374–83. <https://doi.org/10.1021/la500998g>.
9. Bahar, A.A.; Ren, D. Antimicrobial peptides. *Pharmaceuticals* **2013**, *6*, 1543–1575. <https://doi.org/10.3390/ph6121543>.
10. Garvey, M. Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens. *Infect. Dis. Rep.* **2023**, *15*, 454–469. <https://doi.org/10.3390/idr15040046>.

11. Pinilla, G.; Coronado, Y.T.; Chaves, G.; Muñoz, L.; Navarrete, J.; Salazar, L.M.; Taborda, C.P.; Muñoz, J.E. In Vitro Antifungal Activity of LL-37 Analogue Peptides against *Candida* spp. *J. Fungi* **2022**, *7*, 1173. <https://doi.org/10.3390/jof8111173>.
12. Tan, L.T.H.; Chan, K.G.; Pusparajah, P.; Lee, W.L.; Chuah, L.H.; Khan, T.M.; Goh, B.H. Targeting Membrane Lipid a Potential Cancer Cure? *Front. Pharmacol.* **2017**, *8*, 12. <https://doi.org/10.3389/fphar.2017.00012>.
13. Wang, L.; Qiu, L.; Zhou, Z.; Song, L. Research progress on the mollusc immunity in China. *Dev. Comp. Immunol.* **2013**, *39*, 2–10. <https://doi.org/10.1016/j.dci.2012.06.014>.
14. Li, H.; Parisi, M.G.; Parrinello, N.; Cammarata, M.; Roch, P. Molluscan antimicrobial peptides, a review from activity-based evidences to computer-assisted sequences. *Invertebr. Surviv. J.* **2011**, *8*, 85–97.
15. Smith, V.J.; Desbois, A.P.; Dyrinda, E.A. Conventional and unconventional antimicrobials from fish, marine invertebrates and micro-algae. *Mar. Drugs* **2010**, *8*, 1213–1262. <https://doi.org/10.3390/md8041213>.
16. Dolashka, P.; Dolashki, A.; Velkova, L.; Stevanovic, S.; Molin, L.; Traldi, P.; Velikova, R.; Voelter, W. Bioactive compounds isolated from garden Snails. *J. BioSci. Biotechnol.* **2015**, 147–155.
17. Dolashka, P.; Dolashki, A.; Van Beeumen, J.; Floetenmeyer, M.; Velkova, L.; Stevanovic, S.; Voelter, W. Antimicrobial Activity of Molluscan Hemocyanins from *Helix* and *Rapana* Snails. *Curr Pharm Biotechnol.* **2016**, *17*(3), 263-70. <https://doi.org/10.2174/1389201016666150907113435>.
18. Kirilova, M.; Topalova, Y.; Velkova, L.; Dolashki, A.; Kaynarov, D.; Daskalova, E.; Zheleva, N. Antibacterial Action of Protein Fraction Isolated from *Rapana venosa* Hemolymph against *Escherichia coli* NBIMCC 8785. *Pharmaceuticals (Basel)*. **2024**, *17*(1), 68. <https://doi.org/10.3390/ph17010068>.
19. Dolashki A., Velkova L., Daskalova E., Zheleva N., Topalova Y., Atanasov V., Voelter W., Dolashka P. Antimicrobial Activities of Different Fractions from Mucus of the Garden Snail *Cornu aspersum*. *Biomedicines*. **2020**, *8*, 315. <https://doi.org/10.3390/biomedicines8090315>.
20. Pitt, S.; Graham, M.A.; Dedi, C.G.; Taylor-Harris, P.M.; Gunn, A. Antimicrobial properties of mucus from the brown garden snail *Helix aspersa*. *Br. J. Biomed. Sci.* **2015**, *72*, 174–181. <https://doi.org/10.1080/09674845.2015.11665749>.
21. Suárez, L.; Pereira, A.; Hidalgo, W.; Uribe, N. Antibacterial, Antibiofilm and Anti-Virulence Activity of Biactive Fractions from Mucus Secretion of Giant African Snail *Achatina fulica* against *Staphylococcus aureus* Strains. *Antibiotics* **2021**, *10*(12), 1548. <https://doi.org/10.3390/antibiotics10121548>.
22. Etim, L.B.; Aleruchi, C.; Obande, G.A. Antibacterial Properties of Snail Mucus on Bacteria Isolated from Patients with Wound Infection. *British microbiology research journal* **2016**, *11*, 1-9. <https://doi.org/10.9734/BMRJ/2016/21731>.
23. Santana, W.; Melo, C.; Cardoso, J.; Pereira-Filho, R.; Rabelo, A.; Reis, F.; Albuquerque, R.L.C. Assessment of antimicrobial activity and healing potential of mucous secretion of *Achatina fulica*. *International Journal of Morphology* **2012**, *30*, 365–373. <https://doi.org/10.4067/S0717-95022012000200001>.
24. Pitt, S.J.; Hawthorne, J.A.; Garcia-Maya, M.; Alexandrovich, A.; Symonds, R.C.; Gunn, A. Identification and characterisation of anti-*Pseudomonas aeruginosa* proteins in mucus of the brown garden snail, *Cornu aspersum*. *Br. J. Biomed. Sci.* **2019**, *76*, 129–136. <https://doi.org/10.1080/09674845.2019.1603794>.
25. Brieva, A.; Philips, N.; Tejedor, R.; Guerrero, A.; Pivel, J.P.; Alonso-Lebrero, J.L.; Gonzalez, S. Molecular basis for the regenerative properties of a secretion of the mollusk *Cryptomphalus aspersa*. *Skin Pharmacol Physiol* **2008**, *21*(1), 15-22. <https://doi.org/10.1159/000109084>.
26. Kostadinova, N.; Voynikov, Y.; Dolashki, A.; Krumova, E.; Abrashev, R.; Kowalewski, D.; Stevanovic, S.; Velkova, L.; Velikova, R.; Dolashka, P. Antioxidative screening of fractions from the mucus of garden snail *Cornu aspersum*. *Bul. Chem. Com.* **2018**, *50C*, 176–183.
27. Petrov, L.; Kachaunov, M.; Alexandrova, A.; Tsvetanova, E.; Georgieva, A.; Dolashki, A.; Velkova, L.; Dolashka, P. Snail Mucus Protective Effect on Ethanol-Induced Gastric Ulcers in Mice. *Life* **2022**, *12*, 1106. <https://doi.org/10.3390/life12081106>.
28. Zhu, K.; Zhang, Z.; Li, G.; Sun, J.; Gu, T.; Ain, N.U.; Zhang, X.; Li, D. Extraction, structure, pharmacological activities and applications of polysaccharides and proteins isolated from snail mucus. *Int J Biol Macromol.* **2024**, *258*(Pt 1), 128878. <https://doi.org/10.1016/j.ijbiomac.2023.128878>.
29. Deng, T.; Gao, D.; Song, X.; Zhou, Z.; Zhou, L.; Tao, M.; Jiang, Z.; Yang, L.; Luo, L.; Zhou, A.; Hu, L.; Qin, H.; Wu, M. A natural biological adhesive from snail mucus for wound repair. *Nat Commun* **2023**, *14*, 396. <https://doi.org/10.1038/s41467-023-35907-4>

30. Cilia, G.; Fratini, F. Antimicrobial properties of terrestrial snail and slug mucus. *J Complement Integr Med.* **2018**, 15(3), /j/jcim.2018.15.issue-3/jcim-2017-0168/jcim-2017-0168.xml. <https://doi.org/10.1515/jcim-2017-0168>.
31. Ulagesan, S.; Kim, H.J. Antibacterial and Antifungal Activities of Proteins Extracted from Seven Different Snails. *Appl. Sci.* **2018**, 8, 1362. <https://doi.org/10.3390/app8081362>.
32. Cerullo, A.R.; McDermott, M.B.; Pepi, L.E.; et al. Comparative mucomic analysis of three functionally distinct *Cornu aspersum* Secretions. *Nat Commun* **2023**, 14, 5361. <https://doi.org/10.1038/s41467-023-41094-z>.
33. Pietrzyk, A.; Bujacz, A.; Mak, P.; Potempa, B.; Niedziela, T. Structural studies of *Helix aspersa* agglutinin complexed with GalNAc: a lectin that serves as a diagnostic tool. *Int J Biol Macromol.* **2015**, 81, 1059–1068. <https://doi.org/10.1016/j.ijbiomac.2015.09.044>.
34. Greistorfer, S.; Klepal, W.; Cyran, N.; Gugumuck, A.; Rudoll, L.; Suppan, J.; von Byern, J. Snail mucus – glandular origin and composition in *Helix pomatia*. *Zoology* **2017**, 122, 126–138. doi: 10.1016/j.zool.2017.05.001.
35. Herluinus Mafranenda, DNH.; Kriswandini, I.L.; Arijani R.E. Antimicrobial proteins of Snail mucus (*Achatina fulica*) against *Streptococcus mutans* and *Aggregatibacter actinomycetemcomitans*. *Dent. J.* **2014**, 47, 31–36. <https://doi.org/10.20473/j.djmk.v47.i1.p31-36>.
36. Dolashki, A.; Nissimova, A.; Daskalova, E.; Velkova, L.; Topalova, Y.; Hristova, P.; Traldi, P.; Voelter, W.; Dolashka, P. Structure and antibacterial activity of isolated peptides from the mucus of garden snail *Cornu aspersum*. *Bulg. Chem. Commun.* **2018**, 50C, 195–200.
37. Topalova, Y.; Belouhova, M.; Velkova, L.; Dolashki, A.; Zheleva, N.; Daskalova, E.; Kaynarov, D.; Voelter, W.; Dolashka, P. Effect and Mechanisms of Antibacterial Peptide Fraction from Mucus of *C. aspersum* against *Escherichia coli* NBIMCC 8785. *Biomedicines* **2022**, 10, 672. <https://doi.org/10.3390/biomedicines10030672>.
38. Velkova, L.; Nissimova, A.; Dolashki, A.; Daskalova, E.; Dolashka, P.; Topalova, Y. Glycine-rich peptides from *C. aspersum* snail with antibacterial activity. *Bulg. Chem. Commun.* **2018**, 50, 169–175.
39. Meher, P.; Sahu, T.; Saini, V.; Rao, A.R. Predicting antimicrobial peptides with improved accuracy by incorporating the compositional, physico-chemical and structural features into Chou's general PseAAC. *Sci. Rep.* **2017**, 7, 42362. <https://doi.org/10.1038/srep42362>.
40. Pawlicki, J.M.; Pease, L.B.; Pierce, C.M.; Startz, T.P.; Zhang, Y.; Smith, A.M. The effect of molluscan glue proteins on gel mechanics. *J. Exp. Biol.* **2004**, 207, 1127–1135. <https://doi.org/10.1242/jeb.00859>.
41. Tachapuripunya, V.; Roytrakul, S.; Chumnanpuen, P.; E-kobon, T. Unveiling Putative Functions of Mucus Proteins and Their Tryptic Peptides in Seven Gastropod Species Using Comparative Proteomics and Machine Learning-Based Bioinformatics Predictions. *Molecules* **2021**, 26, 3475. <https://doi.org/10.3390/molecules26113475>.
42. Li, D.; Graham, L.D. Epiphragmin, the major protein of epiphragm mucus from the vineyard snail, *Cernuella virgata*. *Comp. Biochem. Physiol. B: Biochem. Mol. Biol.* **2007**, 148, 192–200. <https://doi.org/10.1016/j.cbpb.2007.05.009>.
43. Ballard, K.R.; Klein, A.H.; Hayes, R.A.; Wang, T.; Cummins, S.F. The protein and volatile components of trail mucus in the Common Garden Snail, *Cornu aspersum*. *PLoS ONE* **2021**, 16, e0251565. <https://doi.org/10.1371/journal.pone.0251565>.
44. González García, M.; Rodríguez, A.; Alba, A.; Vázquez, A.A.; Morales Vicente, F.E.; Pérez-Erviti, J.; Spellerberg, B.; Stenger, S.; Grieshober, M.; Conzelmann, C.; et al. New Antibacterial Peptides from the Freshwater Mollusk *Pomacea poeyana* (Pilsbry, 1927). *Biomolecules* **2020**, 10, 1473. <https://doi.org/10.3390/biom10111473>.
45. Ebou, A.; Koua, D.; Addablah, A.; Kakou-Ngazoa, S.; Dutertre, S. Combined Proteotranscriptomic-Based Strategy to Discover Novel Antimicrobial Peptides from Cone Snails. *Biomedicines* **2021**, 9, 344. <https://doi.org/10.3390/biomedicines9040344>.
46. Vassilev, N.G.; Simova, S.D.; Dangalov, M.; Velkova, L.; Atanasov, V.; Dolashki, A.; Dolashka, P. An ¹H NMR- and MS-Based Study of Metabolites Profiling of Garden Snail *Helix aspersa* Mucus. *Metabolites* **2020**, 10, 360. <https://doi.org/10.3390/metabo10090360>.
47. Sousa, J.C.; Berto, R.F.; Gois, E.A.; Fontenele-Cardi, N.C.; Honório-Júnior, J.E.; Konno, K.; Richardson, M.; Rocha, M.F.; Camargo, A.A.; Pimenta, D.C.; Cardi, B.A.; Carvalho, K.M. Leptoglycin: A new Glycine/Leucine-rich antimicrobial peptide isolated from the skin secretion of the South American frog

- Leptodactylus pentadactylus (Leptodactylidae). *Toxicon* **2009**, *54*, 23–32. <https://doi.org/10.1016/j.toxicon.2009.03.011>.
48. Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. *Biochim Biophys Acta*. **2009**, *1788*(8), 1687–92. <https://doi.org/10.1016/j.bbamem.2008.09.013>.
 49. Lei, J.; Sun, L.; Huang, S.; Zhu, C.; Li, P.; He, J.; Mackey, V.; Coy, D.H.; He, Q. The antimicrobial peptides and their potential clinical applications. *Am. J. Transl. Res.* **2019**, *11*, 3919–3931.
 50. Raheem, N.; Straus, S.K. Mechanisms of Action for Antimicrobial Peptides with Antibacterial and Antibiofilm Functions. *Front. Microbiol.* **2019**, *10*, 2866. <https://doi.org/10.3389/fmicb.2019.02866>.
 51. Chen, Y.; Guarnieri, M.T.; Vasil, A.I.; Vasil, M.L.; Mant, C.T.; Hodges, R.S. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. *Antimicrob. Agents Chemother.* **2007**, *51*, 1398–1406. <https://doi.org/10.1128/aac.00925-06>.
 52. Zhong, J.; Wang, W.; Yang, X.; Yan, X.; Liu, R. A novel cysteine-rich antimicrobial peptide from the mucus of the snail of *Achatina fulica*. *Peptides* **2013**, *39*, 1–5. <https://doi.org/10.1016/j.peptides.2012.09.001> Get rights and content.
 53. Breitenbach Barroso Coelho, L.C.; Marcelino Dos Santos Silva, P.; Felix de Oliveira, W.; de Moura, M.C.; Viana Pontual, E.; Soares Gomes, F.; Guedes Paiva, P.M.; Napoleão, T.H.; Dos Santos Correia, M.T. Lectins as antimicrobial agents. *J Appl Microbiol.* **2018**, *125*(5), 1238–1252. <https://doi.org/10.1111/jam.14055>.
 54. Pietrzyk-Brzezinska, A.J.; Bujacz, A. H-type lectins - Structural characteristics and their applications in diagnostics, analytics and drug delivery. *Int J Biol Macromol.* **2020**, *152*, 735–747. doi: 10.1016/j.ijbiomac.2020.02.320.
 55. Prokop, O.; Uhlenbruck, G.; Köhler, W. A new source of antibody-like substances having anti-blood group specificity: a discussion on the specificity of *Helix* agglutinins. *Vox Sang.* **1968**, *14*(5), 321–33. <https://doi.org/10.1111/j.1423-0410.1968.tb01722.x>.
 56. Ito, S.; Shimizu, M.; Nagatsuka, M.; Kitajima, S.; Honda, M.; Tsuchiya, T.; Kanzawa, N. High molecular weight lectin isolated from the mucus of the giant African snail *Achatina fulica*. *Biosci Biotechnol Biochem.* **2011**, *75*(1), 20–5. <https://doi.org/10.1271/bbb.100389>.
 57. Maji, S.; Datta, U.; Hembram, M.Lal. A new sperm agglutinin factor from marine snail *Telescopium telescopium*: An evaluation with goat (*Capra hircus*) cauda epididymal spermatozoa. *Iranian Journal of Reproductive Medicine* **2010**, *8*(1), 10–17.
 58. Coates, C.J.; Nairn, J. Diverse immune functions of hemocyanins. *Dev. Comp. Immunol.* **2014**, *45*, 43–55. <https://doi.org/10.1016/j.dci.2014.01.021>.
 59. Coates, C.J., Costa-Paiva, E.M. Multifunctional Roles of Hemocyanins. *Subcell Biochem.* **2020**, *94*, 233–250. https://doi.org/10.1007/978-3-030-41769-7_9.
 60. Jeyachandran, S.; Chellapandian, H.; Park, K.; Kwak, I.S. Exploring the Antimicrobial Potential and Biofilm Inhibitory Properties of Hemocyanin from *Hemifusus pugilinus* (Born, 1778). *Int J Mol Sci.* **2023**, *24*(14), 11494. <https://doi.org/10.3390/ijms241411494>.
 61. Yang, S.; Huang, H.; Wang, F.; Aweya, J.J.; Zheng, Z.; Zhang, Y. Prediction and characterization of a novel hemocyanin-derived antimicrobial peptide from shrimp *Litopenaeus vannamei*. *Amino Acids.* **2018**, *50*(8), 995–1005. <https://doi.org/10.1007/s00726-018-2575-x>.
 62. Zhuang, J.; Coates, C.J.; Zhu, H.; Zhu, P.; Wu, Z.; Xie, L. Identification of candidate antimicrobial peptides derived from abalone hemocyanin. *Dev. Comp. Immunol.* **2015**, *49*, 96–102. <https://doi.org/10.1016/j.dci.2014.11.008>.
 63. Ehara, T.; Kitajima, S.; Kanzawa, N.; Tamiya, T.; Tsuchiya, T. Antimicrobial action of achacin is mediated by L-amino acid oxidase activity. *FEBS Lett.* **2002**, *531*, 509–12. [https://doi.org/10.1016/S0014-5793\(02\)03608-6](https://doi.org/10.1016/S0014-5793(02)03608-6).
 64. McDermott, M.; Cerullo, A.R.; Parziale, J.; Achrak, E.; Sultana, S.; Ferd, J.; Samad, S.; Deng, W.; Braunschweig, A.B.; Holford, M. Advancing discovery of snail mucins function and application. *Front Bioeng Biotech.* **2021**, *9*, 734023. <https://doi.org/10.3389/fbioe.2021.734023>.
 65. Rashad, M.; Sampò, S.; Cataldi, A.; Zara, S. Biological activities of gastropods secretions: snail and slug slime. *Nat Prod Bioprospect* **2023**, *13*(1), 42. <https://doi.org/10.1007/s13659-023-00404-0>.
 66. Corfield, A.P. Mucins: A Biologically Relevant Glycan Barrier in Mucosal protection. *Biochim. Biophys. Acta* **2015**, *1850*, 236–252. <https://doi.org/10.1016/j.bbagen.2014.05.003>.

67. Bakshani, C.R.; Morales-Garcia, A.L.; Althaus, M.; Wilcox, M.D.; Pearson, J.P.; Bythell, J.C.; Burgess, J.G. Evolutionary conservation of the antimicrobial function of mucus: a first defence against infection. *NPJ Biofilms Microbiome* **2018**, *4*, 14. <https://doi.org/10.1038/s41522-018-0057-2>.
68. Okeniyi, F.A.; Oghenochuko, O.M.; Olawoye, S.O.; Animashahun, R.A.; Adeyolu, A.G.; Akpor O.B. Antimicrobial potentials of mucus mucin from different species of giant African land snails on some typed culture pathogenic bacteria. *Asian J Agric & Biol.* **2022**, *4*, 202107294. <https://doi.org/10.35495/ajab.2021.07.294>.
69. Zhukova, N.V.; Eliseikina, M.G.; Balakirev, E.S.; Ayala, F.J. Multiple bacterial partners in symbiosis with the nudibranch mollusk *Rostanga alisae*. *Sci Rep.* **2022**, *12*(1), 169. <https://doi.org/10.1038/s41598-021-03973-7>.
70. Madian, A.G.; Regnier, F.E. Proteomic identification of carbonylated proteins and their oxidation sites. *J Proteome Res.* **2010**, *9*(8), 3766–80. <https://doi.org/10.1021/pr1002609>.
71. Phrompanya, P.; Suriyaruean, N.; Nantarat, N.; Saenphet, S.; Tragoolpua, Y.; Saenphet, K. Biological properties of mucus from land snails (*Lissachatina fulica*) and freshwater snails (*Pomacea canaliculata*) and histochemical study of mucous cells in their foot. *Peer J.* **2023**, *11*, e15827. <https://doi.org/10.7717/peerj.15827>.
72. Wang, W.; Yi, J.; Ke, S.; Halmela, M. Gastropod biological fluid, method of making and refining and use. **2010**. United States Patent Application 20100233111.
73. Wang, L.; Yang, J.; Wang, Y.; Zhang, J.; Gao, Y.; Yuan, J.; Su, A.; Ju, X. Study on antioxidant activity and amino acid analysis of rapeseed protein hydrolysates. *International Journal of Food Properties* **2016**, *19*, 1899–1911. <https://doi.org/10.1080/10942912.2015.1085397>.
74. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **1976**, *72*, 248–254. [https://doi.org/10.1016/0003-2697\(76\)90527-3](https://doi.org/10.1016/0003-2697(76)90527-3).
75. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **1970**, *227*(5259), 680–5.
76. Lincz, L.F.; Scorgie, F.E.; Garg, M.B.; Gilbert, J.; Sakoff J.A. A simplified method to calculate telomere length from Southern blot images of terminal restriction fragment lengths. *Biotechniques.* **2020**, *68*, 28–34. <https://doi.org/10.2144/btn-2019-0082>.
77. Rosenfeld, J.; Capdevielle, J.; Guillemot, J.C.; Ferrara, P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. *Anal. Biochem.* **1992**, *203*, 173–179. [https://doi.org/10.1016/0003-2697\(92\)90061-B](https://doi.org/10.1016/0003-2697(92)90061-B).
78. CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing; Approved Standard-34th edition; March **2024**.
79. Daskalova, A.; Petrova, V.; Velkova, L.; Kujumdzieva, A.; Tomova, A.; Voelter, W.; Dolashka, P. Investigation of protein expression of *Saccharomyces cerevisiae* cells in quiescent and proliferating state before and after toxic stress. *Biotechnol. Biotechnol. Equip.* **2021**, *35*, 366–376. doi: 10.1080/13102818.2021.1879677.
80. Kostova, I.; Traykova, M.; Rastogi, V.K. New lanthanide complexes with antioxidant activity. *Medicinal Chemistry (Sharjah, United Arab Emirates)* **2008**, *4*(4), 371–378.
81. Mesquita, C.S.; Oliveira, R.; Bento, F.; Geraldo, D.; Rodrigues, J.V.; Marcos, J.C. Simplified 2,4-dinitrophenylhydrazine spectrophotometric assay for quantification of carbonyls in oxidized proteins. *Analytical Biochemistry* **2014**, *485*, 69–71. <https://doi.org/10.1016/j.ab.2014.04.034>.
82. Zhang, Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. *Carcinogenesis* **2000**, *21*(6), 1175–1182. <https://doi.org/10.1093/carcin/21.5.175>.
83. Kumaran, A.; Karunakaran, R.J. Anti-oxidant activity of polyphenols from *Phyllanthus debilis* Klein ex Willd. *J. Nat. Remedies* **2006**, *6*(2), 141 – 146.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.